This will be a study of the ivestigational agent MK-1084, in combination with Keytruda® (pembrolizumab) — in patients not previously treated, but whose lung cancer expresses certain promising PD-L1 levels.
We will follow up, when results are released, in a peer reviewed process, or journal article. Good news for Rahway — and… without further ado, here’s the latest bit:
…The trial, which began enrollment on Monday, will assess the combination therapy’s impact on progression-free survival and overall survival in approximately 600 patients worldwide. These patients have not received prior treatment and have tumors harboring KRAS G12C mutations with PD-L1 expression levels of 50% or higher.
Merck’s decision to proceed with a larger Phase 3 trial follows promising early results from a Phase 1 study, indicating that the MK-1084 and KEYTRUDA combination had a manageable safety profile and showed potential in tumor reduction. Dr. Marjorie Green, senior vice president and head of oncology global clinical development at Merck Research Laboratories, emphasized the significance of targeting KRAS G12C mutations, which are prevalent in NSCLC cases.
Lung cancer remains the leading cause of cancer-related deaths worldwide. Despite advances in early detection, screening, and new therapies, the five-year survival rate in the United States is only 25%. Merck’s latest trial is part of its ongoing commitment to improving outcomes for lung cancer patients through extensive research and clinical trials….
Obviously, if these trials prove out — the combo package becomes a very legit way to extend the life of Keytruda’s exclusivity in the oncology markets, world-wide — for those (relatively few, in terms of the globe’s annual income levels per patient) that are able to afford the therapy.
Now you know. Onward, grinning — no snow, just rain now — and I’ve got Seton Hall in the NIT final tonight.
नमस्ते
Powerline Lies... 